Exosome blood test could spot ovarian cancer return when standard tests fail
NCT ID NCT07153705
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new blood test called OCS that uses exosome technology to monitor for ovarian cancer recurrence. It focuses on patients whose CA125 levels were normal before initial treatment, making standard monitoring difficult. The trial will enroll 32 women with stage I-IV ovarian cancer who have completed surgery and chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OCS exosome detection test
- What this could lead to
- If successful, this could provide a reliable way to detect ovarian cancer recurrence early in patients whose standard CA125 test is not informative.
- What could go wrong
- This is a small, early-stage study with only 32 participants, so results may not apply broadly. The test is experimental and not yet proven to be better than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?